K
v
ire
.com
←
Back
Night
Docs
Library
Critique
…
Author
Stephen L. Abrams
also known as Abrams, Stephen, S Abrams, S L Abrams
Royal Canadian Mounted Police · Pennsylvania State University · The University of Texas MD Anderson Cancer Center · Harvard University
About this author
Works
150
Cited by
9,132
h-index
41
i10
80
ORCID ↗
Top papers
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance
James A. McCubrey, Linda S. Steelman, William H. Chappell, et al.
·
2006
·
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
↗ 2,280
OA
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging
Linda S. Steelman, William H. Chappell, Stephen L. Abrams, et al.
·
2011
·
Aging
↗ 698
OA
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
William H. Chappell, Linda S. Steelman, Jacquelyn M. Long, et al.
·
2011
·
Oncotarget
↗ 575
OA
Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia
Linda S. Steelman, Stephen L. Abrams, Jarrett T. Whelan, et al.
·
2008
·
Leukemia
↗ 396
OA
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance
James A. McCubrey, Linda S. Steelman, William H. Chappell, et al.
·
2012
·
Oncotarget
↗ 315
OA
Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades Which Alter Therapy Response.
James A. McCubrey, Linda S. Steelman, William H. Chappell, et al.
·
2012
·
Oncotarget
↗ 303
OA
Targeting GSK3 and Associated Signaling Pathways Involved in Cancer
Przemysław Duda, Shaw M. Akula, Stephen L. Abrams, et al.
·
2020
·
Cells
↗ 261
OA
Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy
Linda S. Steelman, Richard A. Franklin, Stephen L. Abrams, et al.
·
2011
·
Leukemia
↗ 261
Multifaceted roles of GSK-3 and Wnt/β-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention
James A. McCubrey, Linda S. Steelman, F. E. Bertrand, et al.
·
2013
·
Leukemia
↗ 249
OA
Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention
Nicole D. Armstrong, Melissa L. Sokolosky, Kristin M. Stadelman, et al.
·
2014
·
Oncotarget
↗ 243
OA
Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway
Alberto M. Martelli, Camilla Evangelisti, William H. Chappell, et al.
·
2011
·
Leukemia
↗ 204
Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways
James A. McCubrey, Linda S. Steelman, Christian Kempf, et al.
·
2011
·
Journal of Cellular Physiology
↗ 168